Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
2017/04/06 by Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru +3 · 34 citations
Medicine · #Cardiovascular Function and Risk Factors #Heart Failure Treatment and Management #Pulmonary Hypertension Research and Treatments
paper · pdf · doi:10.1161/circulationaha.116.026807
Abstract
Background: Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Phenotyping patients into pathophysiologically homogeneous groups may enable better targeting of treatment. Obesity is common in HFpEF and has many cardiovascular effects, suggesting that it may be a viable candidate for phenotyping. We compared cardiovascular structure, function, and reserve capacity in subjects with obese HFpEF, those with nonobese HFpEF, and control subjects. Methods: Subjects with obese HFpEF (body mass index ≥35 kg/m 2 ; n=99), nonobese HFpEF (body mass index <30 kg/m 2 ; n=96), and nonobese control subjects free of HF (n=71) underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing. Results: Compared with both subjects with nonobese HFpEF and control subjects, subjects with obese HFpEF displayed increased plasma volume (3907 mL [3563–4333 mL] versus 2772 mL [2555–3133 mL], and 2680 mL [2380–3006 mL]; P <0.0001), more concentric left ventricular remodeling, greater right ventricular dilatation (base, 34±7 versus 31±6 and 30±6 mm, P =0.0005; length, 66±7 versus 61±7 and 61±7 mm, P <0.0001), more right ventricular dysfunction, increased epicardial fat thickness (10±2 versus 7±2 and 6±2 mm; P <0.0001), and greater total epicardial heart volume (945 mL [831–1105 mL] versus 797 mL [643–979 mL] and 632 mL [517–768 mL]; P <0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels. Pulmonary capillary wedge pressure was correlated with body mass and plasma volume in obese HFpEF ( r =0.22 and 0.27, both P <0.05) but not in nonobese HFpEF ( P ≥0.3). The increase in heart volumes in obese HFpEF was associated with greater pericardial restraint and heightened ventricular interdependence, reflected by increased ratio of right- to left-sided heart filling pressures (0.64±0.17 versus 0.56±0.19 and 0.53±0.20; P =0.0004), higher pulmonary venous pressure relative to left ventricular transmural pressure, and greater left ventricular eccentricity index (1.10±0.19 versus 0.99±0.06 and 0.97±0.12; P <0.0001). Interdependence was enhanced as pulmonary artery pressure load increased ( P for interaction <0.05). Compared with those with nonobese HFpEF and control subjects, obese patients with HFpEF displayed worse exercise capacity (peak oxygen consumption, 7.7±2.3 versus 10.0±3.4 and12.9±4.0 mL/min·kg; P <0.0001), higher biventricular filling pressures with exercise, and depressed pulmonary artery vasodilator reserve. Conclusions: Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments.
Cited by
- Obesity, Hypertension, and Cardiac Dysfunction
- Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment
- Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide
- How to diagnose heart failure with preserved ejection fraction
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
- Heart failure with preserved ejection fraction (HFpEF): Diagnosis and management for the general physician
- How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- Exercise Intolerance in Patients With Heart Failure
- A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. [europepmc]
- Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. [europepmc]
- Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. [europepmc]
- Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. [europepmc]
- Obesity paradox in cardiovascular disease: where do we stand? [europepmc]
- Heart Failure With Preserved Ejection Fraction In Perspective. [europepmc]
- Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. [europepmc]
- The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. [europepmc]
- The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. [europepmc]
- Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. [europepmc]
- Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. [europepmc]
- Basic Mechanisms of Diabetic Heart Disease. [europepmc]
- Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. [europepmc]
- Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. [europepmc]
- Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. [europepmc]
- Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney. [europepmc]
- Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. [europepmc]
- Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. [europepmc]
- Cardiac fibrosis. [europepmc]
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction. [europepmc]
- Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. [europepmc]
- Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. [europepmc]
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. [europepmc]
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. [europepmc]
- Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. [europepmc]
Related